Research director Brianna Cartwright presented the oral semaglutide findings at AMCP Nexus in San Diego, using patient data through September 2026.
Recap by typeshit. Post by @truveta on X.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
An ultramarathoner credits BPC-157 for her recovery while pharmacists warn that 'research use only' products skip key safety checks and human data stays thin.
The doctor says more patients have been coming in over recent years after losing a lot of weight on drugs like Ozempic and Mounjaro.
Loading…